Energenesis Biomedical Co

Energenesis Biomedical Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Energenesis Biomedical Co (6657.TW) as of Oct 30, 2026 is 86.96 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 78.53 % — a change of 10.74% (higher).

FCF Conversion

86.96 %

YoY

10.74%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Energenesis Biomedical Co is 2025 86.96 % . FCF Conversion Rate (FCF/EBITDA) of Energenesis Biomedical Co was 2024 78.53 % . It decreases by 10.74% higher compared to the previous year.

The Energenesis Biomedical Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
83.82 TWD
Jan 1, 2019
82.22 TWD
Jan 1, 2020
79.97 TWD
Jan 1, 2021
88.31 TWD
Jan 1, 2022
90.12 TWD
Jan 1, 2023
86.75 TWD
Jan 1, 2024
78.53 TWD
Jan 1, 2025
86.96 TWD
The Energenesis Biomedical Co FCF Conversion history
YEARFCF ConversionYoY
86.96 %+10.74%
78.53 %-9.48%
86.75 %-3.74%
90.12 %+2.05%
88.31 %+10.42%
79.97 %-2.73%
82.22 %-1.92%
83.82 %+16.28%
72.08 %+2.10%
70.60 %-85.70%
493.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Energenesis Biomedical Co Stock analysis

What does Energenesis Biomedical Co do? Energenesis Biomedical Co., Ltd. develops new drugs, focusing on experimental service analysis and reagent sales as its main products. The company's primary new drugs include ENERGI-F703 for diabetic foot ulcers, ENERGI-F701 for abnormal alopecia, ENERGI-F711 for burns, and ENERGI-F706 for cachexia. These products target medical professionals and healthcare institutions seeking innovative treatments for specific conditions. The firm generates revenue through the sale of experimental services and reagents, as well as the commercialization of its drug pipeline. Energenesis Biomedical's product portfolio is centered around four key drug candidates, each addressing distinct medical needs. ENERGI-F703 addresses diabetic foot ulcers, a common complication in diabetes management, while ENERGI-F701 targets abnormal alopecia, a condition affecting hair growth. ENERGI-F711 is designed for burn treatment, and ENERGI-F706 focuses on cachexia, a wasting syndrome often associated with chronic diseases. These drugs are developed for direct sales to healthcare providers and institutions. The company's revenue streams are derived from two main areas: the sale of experimental service analysis and reagent products, alongside the future commercialization of its drug candidates. Healthcare institutions and medical professionals are the primary buyers of these products, seeking advanced solutions for diabetic foot ulcers, alopecia, burns, and cachexia. Energenesis Biomedical's business model relies on the successful development and market entry of its drug pipeline to generate sustained revenue. Energenesis Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Energenesis Biomedical Co stock

FCF Conversion Rate (FCF/EBITDA) of Energenesis Biomedical Co is 86.96 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Energenesis Biomedical Co changed from 78.53 % to 86.96 %, representing a 10.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Energenesis Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Energenesis Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Energenesis Biomedical Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Energenesis Biomedical Co